Northwestern University

Company

Related News

BioNTech, BioLineRx Unveil Clinical Data at ASCO 2026

BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.

Related Clinical Trials

NCT ID Title Status Phase
NCT07775625

Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music

RECRUITING NA
NCT07748611

SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

NOT_YET_RECRUITING PHASE2
NCT07742189

Medication Collaboration Feasibility Study

RECRUITING NA
NCT07732179

Aromatherapy and Music Impact on Nurses' Stress at Work

RECRUITING NA
NCT07729436

Healthy Options At Pantries (HOAP) Study

NOT_YET_RECRUITING NA
NCT07728708

Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease

NOT_YET_RECRUITING
NCT07724652

The AYA Oncology Self-care Movement

NOT_YET_RECRUITING NA
NCT07710105

Ocrevus Zunovo for MS: Mixed Methods

RECRUITING
NCT07707466

Social Robots Empowering Patients

COMPLETED NA
NCT07669753

Advancing Cancer Control Engaged Research Through Transformative Solutions (ACCERT) Social Determinants of Health (SDoH) Navigation Program

RECRUITING NA